# Ocuphire Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ocuphire-pharma

- Industry: Biotechnology
- Headquarters: Farmington Hills, US
- Website: www.ocuphire.com
- Total disclosed funding: $5M
- Latest round: Seed (Jul 22, 2019)
- Investors on record: 9

## About

Ocuphire Pharma, Inc. is a biopharmaceutical company focused on addressing unmet medical needs in ophthalmology through innovative product development for eye disorders.Founded in 2018 and headquartered in Farmington Hills, US, Ocuphire Pharma specializes in developing therapies for ophthalmic conditions. The company has not undergone significant business pivots. It has completed 3 deals with the most recent funding round occurring on January 21, 2020, where it raised USD 2.13 mn. The company is co-led by CEO George Magrath alongside Mina Sooch.Ocuphire Pharma specializes in developing treatments for various ophthalmic conditions. Their product offerings are centered on innovative solutions targeting eye disorders, including therapies that aim to improve vision and overall eye health. These products are designed for healthcare providers, specialized clinics, and research institutions primarily in North America and Europe.Ocuphire Pharma generates revenue through partnerships and collaborations with healthcare institutions and research organizations. The company typically engages in structured agreements to facilitate the development and distribution of its therapies, which include licensing deals and collaborative research agreements focusing on the complexities of regulatory compliance and the transformative potential of their treatments.Ocuphire Pharma plans to advance its product pipeline by launching new therapies designed for specific ophthalmic conditions in the coming years. The company aims to expand its market presence beyond North America and Europe into other global regions by 2024. The recent venture funding of USD 2.13 mn will be utilized to support these growth initiatives, including further development of their therapeutic offerings.

## Funding rounds

- Seed, Jul 22, 2019, $5M — Belle Capital, Grand Angels, Blue Water Angels, Michigan Angel Fund, Biosciences Research & Commercialization Center, First Capital Fund, RBI Opportunities Fund, Ann Arbor Angels, Woodward Angels

## Investors

- Belle Capital (https://capitalatlas.ai/funds/belle-capital) — Seed
- Grand Angels — Seed
- Blue Water Angels — Seed
- Michigan Angel Fund (https://capitalatlas.ai/funds/michigan-angel-fund) — Seed
- Biosciences Research & Commercialization Center (https://capitalatlas.ai/funds/biosciences-research-commercialization-center) — Seed
- First Capital Fund (https://capitalatlas.ai/funds/first-capital-fund) — Seed
- RBI Opportunities Fund — Seed
- Ann Arbor Angels — Seed
- Woodward Angels (https://capitalatlas.ai/funds/woodward-angels) — Seed